nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—Ziprasidone—CHRM3—nephrolithiasis	0.046	1	CrCbGaD
Lurasidone—Creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0364	0.0545	CcSEcCtD
Lurasidone—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0311	0.0466	CcSEcCtD
Lurasidone—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0278	0.0416	CcSEcCtD
Lurasidone—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.0216	0.0324	CcSEcCtD
Lurasidone—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.0213	0.0319	CcSEcCtD
Lurasidone—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.0161	0.024	CcSEcCtD
Lurasidone—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.016	0.0239	CcSEcCtD
Lurasidone—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0149	0.0222	CcSEcCtD
Lurasidone—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0221	CcSEcCtD
Lurasidone—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.0147	0.022	CcSEcCtD
Lurasidone—HTR7—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0137	0.0478	CbGpPWpGaD
Lurasidone—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.013	0.0195	CcSEcCtD
Lurasidone—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.0127	0.019	CcSEcCtD
Lurasidone—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.0127	0.019	CcSEcCtD
Lurasidone—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.0126	0.0188	CcSEcCtD
Lurasidone—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0184	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0183	CcSEcCtD
Lurasidone—Influenza—Hydrochlorothiazide—nephrolithiasis	0.012	0.018	CcSEcCtD
Lurasidone—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.012	0.018	CcSEcCtD
Lurasidone—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0175	CcSEcCtD
Lurasidone—HTR7—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0115	0.0402	CbGpPWpGaD
Lurasidone—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0168	CcSEcCtD
Lurasidone—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0168	CcSEcCtD
Lurasidone—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0166	CcSEcCtD
Lurasidone—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0164	CcSEcCtD
Lurasidone—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0162	CcSEcCtD
Lurasidone—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0158	CcSEcCtD
Lurasidone—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0156	CcSEcCtD
Lurasidone—HTR1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0101	0.0354	CbGpPWpGaD
Lurasidone—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00999	0.015	CcSEcCtD
Lurasidone—ADRA2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0098	0.0343	CbGpPWpGaD
Lurasidone—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00979	0.0146	CcSEcCtD
Lurasidone—DRD2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00889	0.0311	CbGpPWpGaD
Lurasidone—HTR2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00875	0.0306	CbGpPWpGaD
Lurasidone—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00859	0.0129	CcSEcCtD
Lurasidone—HTR1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00851	0.0298	CbGpPWpGaD
Lurasidone—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00824	0.0123	CcSEcCtD
Lurasidone—ADRA2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00824	0.0288	CbGpPWpGaD
Lurasidone—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00809	0.0121	CcSEcCtD
Lurasidone—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00804	0.012	CcSEcCtD
Lurasidone—ADRA2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00796	0.0278	CbGpPWpGaD
Lurasidone—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00789	0.0118	CcSEcCtD
Lurasidone—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00784	0.0117	CcSEcCtD
Lurasidone—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00773	0.0116	CcSEcCtD
Lurasidone—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00769	0.0115	CcSEcCtD
Lurasidone—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00765	0.0114	CcSEcCtD
Lurasidone—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00755	0.0113	CcSEcCtD
Lurasidone—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00752	0.0113	CcSEcCtD
Lurasidone—Syncope—Hydrochlorothiazide—nephrolithiasis	0.0075	0.0112	CcSEcCtD
Lurasidone—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00749	0.0112	CcSEcCtD
Lurasidone—DRD2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00748	0.0261	CbGpPWpGaD
Lurasidone—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00736	0.0257	CbGpPWpGaD
Lurasidone—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00735	0.011	CcSEcCtD
Lurasidone—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00712	0.0107	CcSEcCtD
Lurasidone—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0071	0.0106	CcSEcCtD
Lurasidone—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00697	0.0104	CcSEcCtD
Lurasidone—Shock—Hydrochlorothiazide—nephrolithiasis	0.00672	0.0101	CcSEcCtD
Lurasidone—ADRA2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00669	0.0234	CbGpPWpGaD
Lurasidone—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00666	0.00998	CcSEcCtD
Lurasidone—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.0066	0.00988	CcSEcCtD
Lurasidone—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00638	0.00955	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00622	0.00931	CcSEcCtD
Lurasidone—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00925	CcSEcCtD
Lurasidone—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00609	0.00911	CcSEcCtD
Lurasidone—HTR7—GPCRs, Other—CHRM3—nephrolithiasis	0.00607	0.0212	CbGpPWpGaD
Lurasidone—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00607	0.00909	CcSEcCtD
Lurasidone—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00601	0.009	CcSEcCtD
Lurasidone—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00594	0.00889	CcSEcCtD
Lurasidone—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00589	0.00881	CcSEcCtD
Lurasidone—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00558	0.00836	CcSEcCtD
Lurasidone—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.0054	0.00808	CcSEcCtD
Lurasidone—ADRA2C—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.00498	0.0174	CbGpPWpGaD
Lurasidone—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0049	0.00734	CcSEcCtD
Lurasidone—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00483	0.00723	CcSEcCtD
Lurasidone—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00467	0.007	CcSEcCtD
Lurasidone—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00452	0.00676	CcSEcCtD
Lurasidone—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00434	0.0065	CcSEcCtD
Lurasidone—HTR7—G alpha (s) signalling events—PTH—nephrolithiasis	0.00434	0.0152	CbGpPWpGaD
Lurasidone—HTR1A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00431	0.0151	CbGpPWpGaD
Lurasidone—Rash—Hydrochlorothiazide—nephrolithiasis	0.00431	0.00645	CcSEcCtD
Lurasidone—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.0043	0.00644	CcSEcCtD
Lurasidone—ADRA2C—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00417	0.0146	CbGpPWpGaD
Lurasidone—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00406	0.00607	CcSEcCtD
Lurasidone—ADRA2A—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.00404	0.0141	CbGpPWpGaD
Lurasidone—ADRA2C—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00391	0.0137	CbGpPWpGaD
Lurasidone—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.00389	0.0136	CbGpPWpGaD
Lurasidone—DRD2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00379	0.0132	CbGpPWpGaD
Lurasidone—ADRA2A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00339	0.0118	CbGpPWpGaD
Lurasidone—ADRA2A—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00318	0.0111	CbGpPWpGaD
Lurasidone—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00302	0.0106	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00296	0.0104	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0027	0.00945	CbGpPWpGaD
Lurasidone—HTR7—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00264	0.00922	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00241	0.00841	CbGpPWpGaD
Lurasidone—HTR7—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00226	0.0079	CbGpPWpGaD
Lurasidone—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00218	0.00764	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—RGS14—nephrolithiasis	0.00199	0.00696	CbGpPWpGaD
Lurasidone—HTR1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00195	0.00683	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00195	0.00683	CbGpPWpGaD
Lurasidone—ADRA2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00189	0.00661	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—RGS14—nephrolithiasis	0.00181	0.00632	CbGpPWpGaD
Lurasidone—HTR7—GPCR ligand binding—CHRM3—nephrolithiasis	0.00172	0.00602	CbGpPWpGaD
Lurasidone—DRD2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00172	0.006	CbGpPWpGaD
Lurasidone—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00169	0.0059	CbGpPWpGaD
Lurasidone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00167	0.00585	CbGpPWpGaD
Lurasidone—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00162	0.00566	CbGpPWpGaD
Lurasidone—HTR7—GPCR ligand binding—PTH—nephrolithiasis	0.00157	0.0055	CbGpPWpGaD
Lurasidone—ADRA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00154	0.00537	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—SLC7A9—nephrolithiasis	0.00153	0.00534	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—DGKH—nephrolithiasis	0.00153	0.00534	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00148	0.00516	CbGpPWpGaD
Lurasidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00147	0.00514	CbGpPWpGaD
Lurasidone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00145	0.00506	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.00143	0.00499	CbGpPWpGaD
Lurasidone—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.0014	0.00491	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—DGKH—nephrolithiasis	0.00135	0.0047	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—RGS14—nephrolithiasis	0.00134	0.00468	CbGpPWpGaD
Lurasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00132	0.0046	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—RGS14—nephrolithiasis	0.0013	0.00453	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—RGS14—nephrolithiasis	0.0013	0.00453	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00128	0.00446	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00127	0.00446	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ADCY10—nephrolithiasis	0.00126	0.00439	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—SLC7A9—nephrolithiasis	0.00124	0.00433	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—DGKH—nephrolithiasis	0.00124	0.00433	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.00123	0.00431	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—DGKH—nephrolithiasis	0.00122	0.00427	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—RGS14—nephrolithiasis	0.00118	0.00411	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—PTH—nephrolithiasis	0.00117	0.00408	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00116	0.00405	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00116	0.00405	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—PTH—nephrolithiasis	0.00113	0.00395	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00112	0.00391	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.0011	0.00385	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—RGS14—nephrolithiasis	0.00107	0.00373	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00105	0.00368	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—PTH—nephrolithiasis	0.00102	0.00358	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.00101	0.00352	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.001	0.0035	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000997	0.00348	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000973	0.0034	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000965	0.00337	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000931	0.00325	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—PTH—nephrolithiasis	0.000917	0.0032	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GRHPR—nephrolithiasis	0.000916	0.0032	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—DGKH—nephrolithiasis	0.000905	0.00316	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000901	0.00315	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—PTH—nephrolithiasis	0.000889	0.00311	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CHRM3—nephrolithiasis	0.000883	0.00309	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000876	0.00306	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000875	0.00306	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000861	0.00301	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ADCY10—nephrolithiasis	0.000817	0.00286	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AGXT—nephrolithiasis	0.000817	0.00285	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—PTH—nephrolithiasis	0.000808	0.00282	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000804	0.00281	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—DGKH—nephrolithiasis	0.000795	0.00278	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RGS14—nephrolithiasis	0.000792	0.00277	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000783	0.00274	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.000782	0.00273	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RGS14—nephrolithiasis	0.000766	0.00268	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GRHPR—nephrolithiasis	0.000744	0.0026	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000732	0.00256	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000722	0.00252	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—DGKH—nephrolithiasis	0.000722	0.00252	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000721	0.00252	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.000711	0.00249	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000697	0.00244	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RGS14—nephrolithiasis	0.000695	0.00243	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—APRT—nephrolithiasis	0.000694	0.00243	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—SLC26A1—nephrolithiasis	0.000694	0.00243	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.000684	0.00239	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AGXT—nephrolithiasis	0.000663	0.00232	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—PTH—nephrolithiasis	0.000659	0.0023	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000654	0.00229	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000638	0.00223	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000633	0.00221	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000633	0.00221	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000623	0.00218	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RGS14—nephrolithiasis	0.000622	0.00217	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PTH—nephrolithiasis	0.000599	0.00209	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PTH—nephrolithiasis	0.000579	0.00202	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PTH—nephrolithiasis	0.000579	0.00202	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000575	0.00201	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000569	0.00199	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000566	0.00198	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000565	0.00198	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—APRT—nephrolithiasis	0.000564	0.00197	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—SLC26A1—nephrolithiasis	0.000564	0.00197	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000535	0.00187	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—DGKH—nephrolithiasis	0.000535	0.00187	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PTH—nephrolithiasis	0.000526	0.00184	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CHRM3—nephrolithiasis	0.000522	0.00182	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000518	0.00181	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000517	0.00181	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—DGKH—nephrolithiasis	0.000517	0.00181	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.000517	0.00181	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000514	0.0018	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AQP1—nephrolithiasis	0.000495	0.00173	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PTH—nephrolithiasis	0.000477	0.00167	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PTH—nephrolithiasis	0.00047	0.00164	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00047	0.00164	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—DGKH—nephrolithiasis	0.00047	0.00164	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.000462	0.00161	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000462	0.00161	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CHRM3—nephrolithiasis	0.000447	0.00156	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00042	0.00147	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—DGKH—nephrolithiasis	0.00042	0.00147	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AQP1—nephrolithiasis	0.000402	0.0014	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000387	0.00135	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000374	0.00131	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CHRM3—nephrolithiasis	0.000363	0.00127	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTH—nephrolithiasis	0.000354	0.00124	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTH—nephrolithiasis	0.000342	0.0012	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CHRM3—nephrolithiasis	0.000339	0.00119	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000334	0.00117	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000317	0.00111	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTH—nephrolithiasis	0.00031	0.00109	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTH—nephrolithiasis	0.000305	0.00107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000304	0.00106	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000283	0.000988	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTH—nephrolithiasis	0.000278	0.000971	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APRT—nephrolithiasis	0.00024	0.00084	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.00024	0.00084	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SPP1—nephrolithiasis	0.00024	0.000837	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SPP1—nephrolithiasis	0.000178	0.000621	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SPP1—nephrolithiasis	0.000172	0.0006	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.000171	0.000598	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SPP1—nephrolithiasis	0.000156	0.000545	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CHRM3—nephrolithiasis	0.000155	0.000541	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	0.000153	0.000536	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SPP1—nephrolithiasis	0.00014	0.000488	CbGpPWpGaD
